Sanofi announces takeover of Bioverativ

Sanofi has agreed an $11.6 billion (GBP 8.34 billion) deal to acquire Bioverativ, a biopharmaceutical company focused on therapies for haemophilia and other rare blood disorders.

Bioverativ is known for offering a range of extended half-life therapies for haemophilia, including Eloctate and Alprolix. These two drugs represented the first major advancements in the haemophilia market in nearly two decades when they launched.

The acquisition of the company expands Sanofi's specialty care capabilities, giving the firm control over promising new projects such as a drug that is currently undergoing phase III testing for cold agglutinin disease, and early-stage research programmes and collaborations for blood disorders such as sickle cell disease and beta thalassemia.

Sanofi's research capabilities will help Bioverativ bring these important therapies to patients sooner, while its global presence, proven expertise and success in launching specialty medicines will maximise their worldwide reach.

Olivier Brandicourt, Sanofi's chief executive officer, said: "Combined, we will continue to leverage our scientific knowhow, disciplined focus and development expertise that best position us to drive value for our shareholders and create breakthrough treatments for patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.